Skip to content

Clinical Efficacy and Central Mechanisms of Scalp Acupuncture in the Sun’s Emotional Area for Treating Post-Stroke Cognitive Impairment: An EEG-Based Study

Clinical Efficacy and Central Mechanisms of Scalp Acupuncture in the Sun’s Emotional Area for Treating Post-Stroke Cognitive Impairment: An EEG-Based Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092200
Enrollment
Unknown
Registered
2024-11-12
Start date
2023-04-01
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post stroke cognitive impairment

Interventions

Trial group 1:The subject's emotional area is stimulated by repetitive transcranial acupuncture stimulation
Trial group 2:The subject's emotional area is stimulated by electroacupuncture
Control group:The subject's emotional area is stimulated by minimal twisting stimulation .
Health group:None

Sponsors

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for PSCI disorder in the 2021 edition of the Expert Consensus on the Management of Cognitive Impairment after Stroke; 2. Right hand; 3. Age 35~75 years old, gender is not limited, the course of the disease is within 6 months; 4. Conscious, stable condition, able to cooperate with the completion of the test; 5. No serious motor, speech, hearing, visual impairment, and other diseases that affect the evaluation of efficacy; 6. No serious heart, lung and kidney damage; 7. No psychotropic medication within 7 days; 8. No cognitive dysfunction disease before stroke; 9. Agree and sign the informed consent form

Exclusion criteria

Exclusion criteria: 1. Diagnosed with cognitive dysfunction diseases such as Alzheimer's disease and Lewy body dementia before stroke; 2. MoCA scale score= 22 points; 3. Those who have severe visual, hearing, speech and motor impairments, unstable vital signs, and are unable to complete the examination; 4. Accompanied by severe cardiac, lung, kidney, liver, hematopoietic and endocrine damage; 5. Pregnant or lactating women; 6. Patients with severe mental illness, previous epilepsy, depression, schizophrenia, etc.; 7. Before EEG monitoring, the patient is taking or has used drugs that act on the central nervous system, such as sedative-hypnotic, antiepileptic and antipsychotic drugs, within 7 days;

Design outcomes

Primary

MeasureTime frame
Minimum Mental State Examination;EEG power spectral density parameters;EEG microstate parameters;

Secondary

MeasureTime frame
Montreal Cognitive Assessment;Auditory Verbal Learning Test;Trail Making Test;

Countries

China

Contacts

Public ContactDongyan Wang

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine

532257395@qq.com+86 188 4617 8610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026